EXHIBIT A

Report # 13 to Safe Science, Inc.

In Vivo Evaluation of Safe Science, Inc. Agent GBC590B Alone and in Combination with Interferon–α2b against the Panc-1 Human Pancreatic Carcinoma Xenograft

PIEDMONT RESEARCH CENTER

3300 Gateway Centre

MORRISVILLE, NC 27560

Tel. (919) 462-8338 - Fax (919) 462-8339

[redacted]

Report Prepared By: Daniel Dexter/am
Daniel Dexter, Ph.D.

Statistics Analyzed By: Ben Weigler/am
Ben Weigler, Ph.D., DVM

Study Conducted By: Robin Ball/am
Robin Ball, RLAT

Report Reviewed By: Shih-Fong Chen
Shih-Fong Chen, Ph.D.

Report Approved By:
Beth A.Hollister

D May 16, 2000

Executive Summary

Piedmont Research Center (PRC) has conducted a number of with agent GBC590B, a novel cancer drug candidate submitted by Safe Science, Inc. (Safe Science). In previous tests, a subset of nude mice bearing the Panc-1 human pancreatic carcinoma xenograft has responded to GBC590B, including some long-term survivors (Report No. 3, September 14, 1998 and Report No. 11, January 20, 2000). These results are interesting because pancreatic cancer is a very difficult disease to treat successfully, and the Panc-1 xenograft model is considered representative of this tumor type. To extend these earlier findings, Safe Science has designed a study in the Panc-1 model using GBC590B alone or in combination with interferon-α2b (IFN).

The treatment plan for this experiment is presented in the protocol design shown in Table 1. Mice were pair-matched on Day 1 into six groups of ten animals each. Group 1 received vehicle (saline) on Days 1, 2, 4, 6, 8, 10, 12 and 14. Groups 2, 4, 5 and 6 were administered GBC590B i.v. at a dose of 6.4 mg/kg on Days 1, 2, 4, 6, 8, 10, 12 and 14. Groups 3 and 4 received IFN s.c. at 10×10^6 U/kg on a qd x 14 schedule. Groups 5 and 6 were administered IFN s.c. at doses of 5×10^6 U/kg and 2.5×10^6 U/kg respectively. The test was terminated on Day 60. Responses were assessed by survival extension compared to matched monotherapy or control groups, and by number of tumor regressions at the end of the study.

GBC590B did not produce efficacy in this study as a single agent, or in combination with interferon. There was not a subset of mice receiving GBC590B monotherapy alive on Day 60, but five CRs were documented among thirty animals treated with GBC590B and interferon (at these dose levels). However, a thorough statistical analysis could not demonstrate statistical significance for these few long term survivors. The reason no long term responders was achieved with GBC590B monotherapy in this test, unlike results in prior studies (Reports No. 3 and No. 11), is likely because of biological variation in the response of tumor-bearing mice to an agent that produces a variable level of efficacy. PRC will be happy to discuss other experiments evaluating GBC590B with drugs or

biologicals in solid tumor xenograft models, including melanoma which is responsive to interferon in certain situations.

Introduction

Piedmont Research Center (PRC) has conducted a number of studies over the past two years with agent GBC590B, a novel cancer drug candidate submitted by Safe Science, Inc. (Safe Science). In previous tests, a subset of nude mice bearing the Panc-1 human pancreatic carcinoma xenograft has responded to GBC590B, including some long-term survivors (Report No. 3, September 14, 1998 and Report No. 11, January 20, 2000). These results are interesting because pancreatic cancer is a very difficult disease to treat successfully, and the Panc-1 xenograft model is considered representative of this tumor type. To extend these earlier findings, Safe Science has designed a study in the Panc-1 model using GBC590B alone or in combination with interferon-α2b (IFN). The results of this study are presented in this report.

Methods

Husbandry: Female *nu/nu* mice (Harlan), 12 - 13 weeks of age (at pair-match; Day 1), were fed *ad libitum* water (reverse osmosis, 0.17% Cl) and an autoclaved standard rodent (PICOLAB Mouse Diet 20) diet consisting of: 20% protein; 9% fat; 4% fiber; 6.5% ash; 13.0% moisture, and 2.5% minerals. Mice were housed in static microisolators on a 12-hour light cycle at 21 - 22° C (70 - 72 ° F) and 40% - 60% humidity. PRC specifically complies with recommendations of the *Guide for Care and Use of Laboratory Animals* with respect to restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care. The animal care and use program at PRC is AAALAC accredited.

Tumor Implantation: Female nude mice were implanted subcutaneously with 1 mm^3 Panc-1 human pancreatic carcinoma fragments in the flank. Tumors were monitored twice weekly and then daily as the neoplasms reached the desired size range, approximately 100 mg. When the carcinomas reached a size range of 62 - 196 mg, the

animals were pair-matched into the various treatment groups (group mean tumor weights ranged from 113 - 114 mg). Estimated Panc-1 weight was calculated using the formula:

$$\text{Tumor Weight (mg)} = \frac{w^2 \times l}{2}$$

Where w = width and l = length in mm of a pancreatic carcinoma.

Drugs: GBC590B was supplied by Safe Science, along with instructions for preparation of the injectable material. Saline was needed to dilute GBC590B to the appropriate concentration for dosing. Interferon-α2b was obtained from Schering® Corporation as the pharmaceutical drug and was diluted with saline.

Treatment: The treatment plan for this experiment is presented in the protocol design shown in Table 1. Mice were pair-matched on Day 1 into six groups of ten animals each. Group 1 received vehicle (saline) on Days 1, 2, 4, 6, 8, 10, 12 and 14. Groups 2, 4, 5 and 6 were administered GBC590B i.v. at a dose of 6.4 mg/kg on Days 1, 2, 4, 6, 8, 10, 12 and 14. Groups 3 and 4 received IFN s.c. at 10×10^6 U/kg on a qd x 14 schedule. Groups 5 and 6 were administered IFN s.c. at doses of 5×10^6 U/kg and 2.5×10^6 U/kg respectively. The test was terminated on Day 60.

Endpoint: The tumor growth delay (TGD) method was used in this study. In the TGD method, each animal was euthanized when its Panc-1 neoplasm reached a size of 1.2 g. Mean Day of Survival (MDS) values were calculated for all groups. The MDS values were calculated for each group based on the calculated day of death of each mouse as given by the formula:

$$\text{Time to endpoint (calculated)} = \text{Time to exceed endpoint (observed)} - \frac{Wt_2 - \text{endpoint weight}}{\frac{Wt_2 - Wt_1}{D_2 - D_1}}$$

where:

Time to exceed endpoint (observed) = number of days it takes for each tumor to grow past the endpoint (cut-off) size. This is the day the animal is euthanized as a cancer death.

D_2 = day animal is euthanized.

D_1 = last day of caliper measurement before tumor reaches the endpoint.

Wt_2 = tumor weight (mg) on D_2

Wt_1 = tumor weight (mg) on D_1

Endpoint weight = predetermined "cut-off" tumor size for the model being used.

Treatment may cause complete tumor regression (CR), or partial tumor regression (PR) in an animal. Also, therapy may limit the growth of the neoplasm to a small size that does not reach the 1.2 g cut-off by the termination of the study. This latter condition is called stable disease. The duration of a CR, PR or stable disease response in a host was recorded throughout the study.

Toxicity: Animals were weighed twice weekly during the study. Mice were examined frequently for clinical signs of any adverse, drug-related side effects. Acceptable toxicity for cancer drugs in mice is defined by the NCI as a mean group weight loss of 20% or less during the test, and not more than one toxic death among ten treated animals.

Statistics: Descriptive statistics and stem-and-leaf plots were used to explore the distribution of TGD values over treatment groups, including the number and type of censored observations, as justification for the statistical approach to hypothesis testing of any treatment-related differences. The nonparametric Mann-Whitney test was used to evaluate significance of therapy on TGD, excluding censored observations. Kaplan-Meier plots were also constructed and the log-rank test was used to compare survival distributions for groups receiving IFN-α2b. Fisher's Exact test and binomial distributions were used to evaluate independence of the number of surviving mice. All hypothesis

tests were done at a Type I error rate of 5%, and SPSS for Windows (Release 8.0) was used for the analyses.

Results

Efficacy

Vehicle Control: All nine Panc-1 carcinomas grew progressively, and reached the 1.2 g cut-off with a calculated MDS value of 22.6 days. The summary of MDS values and categories and numbers of responses is shown in Table 2. The scattergram plot of individual animal survival times is depicted in Figure 1. The Kaplan-Meier plot of survival is depicted in Figure 2. The individual animal tumor caliper measurements and body weights (raw data) are appended to the report (Appendices A and B).

Treatment Groups: The MDS values determined for the five treatment groups are essentially equal to (or less than) the MDS = 22.6 days determined for the control Group 1. One, two, and two CRs were documented on Day 60 for combination therapy groups 4, 5, and 6 respectively (Table 2 and Figures 1 and 2). However, statistical analyses including Kaplan-Meier and Log Rank tests demonstrated that there are no significant differences in survivors between any groups at the $p = 0.05$ level.

Side Effects

All treatments were very well-tolerated. In general, mean group body weight increased during the experiment, and no toxic deaths occurred (Table 2 and Appendix A).

Discussion

GBC590B did not produce efficacy in this study as a single agent, or in combination with interferon. There was not a subset of mice receiving GBC590B monotherapy alive on Day 60, but five CRs were documented among thirty animals treated with GBC590B and interferon (at these dose levels). However, a thorough statistical analysis could not demonstrate statistical significance for these few long term survivors. The reason no long term responders was achieved with GBC590B monotherapy in this test, unlike results in prior studies (Reports No. 3 and No. 11), is likely because of biological variation in the response of tumor-bearing mice to an agent that produces a variable level of efficacy. PRC will be happy to discuss other experiments evaluating GBC590B with drugs or biologicals in solid tumor xenograft models, including melanoma which is responsive to interferon in certain situations.

Statistical Analysis by Ben Weigler, Ph.D., DVM

Descriptive statistics and stem-and-leaf plots were used to explore the distribution of TGD values over treatment groups, including the number and type of censored observations, as justification for the statistical approach to hypothesis testing of any treatment-related differences. The nonparametric Mann-Whitney test was used to evaluate significance of therapy on TGD, excluding censored observations. Kaplan-Meier plots were also constructed and the log-rank test was used to compare survival distributions for groups receiving IFN-á2b. Fisher's Exact test and binomial distributions were used to evaluate independence of the number of surviving mice. All hypothesis tests were done at a Type I error rate of 5%, and SPSS for Windows (Release 8.0) was used for the analyses.

A thorough statistical analysis could not demonstrate statistical significance for the few long term survivors noted in Group 4 (GBC590B, 6.4 mg/kg and IFN-á2b, 10×10^6 U/kg; n = 1), Group 5 (GBC590B, 6.4 mg/kg and IFN-á2b, 5×10^6 U/kg; n = 2), and Group 6 (GBC590B, 6.4 mg/kg and IFN-á2b, 2.5×10^6 U/kg; n = 2).

Figure 1

Survival Times for Individual Mice in the Panc1-e20 Study



GBC590B administered at 6.4 mg/kg
IFN(10) = IFN-α2b administered at 10×10^6 U/kg
IFN(5) = IFN-α2b administered at 5×10^6 U/kg
IFN(2.5) = IFN-α2b administered at 2.5×10^6 U/kg

Figure 2

Kaplan-Meier Survival Plot for Mice in the Panc1-e20 Study



GBC590B administered at 6.4 mg/kg

IFN(10) = IFN-α2b administered at 10×10^6 U/kg

IFN(5) = IFN-α2b administered at 5×10^6 U/kg

IFN(2.5) = IFN-α2b administered at 2.5×10^6 U/kg

MAY-26-2000 FRI 09:59 AM SAFESCIENCE INC FAX NO. 6174220675 P. 12

Table 2

Response Summary for the Panc-e20 Study

Group	n	Regimen 1		Regimen 2		MDS to 1.2 g ± SEM (n)	# Toxic Deaths	# of Survivors	# CR	# PR	# Stable Disease
		Agent	mg/kg	Agent	mg/kg						
1	10	Vehicle	---	---	---	22.6 ± 1.9 (9)	1[a]	0	0	0	0
2	10	GBC590B	6.4	---	---	23.0 ± 2.4 (10)	0	0	0	0	0
3	10	IFN-α2b	10×10^6 Units/kg	---	---	21.9 ± 1.8 (10)	0	0	0	0	0
4	10	GBC590B	6.4	IFN-α2b	10×10^6 Units/kg	20.9 ± 1.6 (9)	0	1	1	0	0
5	10	GBC590B	6.4	IFN-α2b	5×10^6 Units/kg	20.1 ± 1.0 (8)	0	2	2	0	0
6	10	GBC590B	6.4	IFN-α2b	2.5×10^6 Units/kg	20.3 ± 2.0 (8)	0	2	2	0	0

[a]The mouse escaped and was euthanized.

FAX NO. 6174220615 P. 10

Table 1

Protocol Design for the Panc-e20 Study

Group	n	Treatment Regimen 1				Treatment Regimen 2			
		Agent	mg/kg	Route	Schedule	Agent	mg/kg	Route	Schedule
1	10	Vehicle	---	iv	D1,2,4,6,8,10,12,14	---	---	---	---
2	10	GBC590B	6.4	iv	D1,2,4,6,8,10,12,14	---	---	---	---
3	10	IFN-α2b	10×10^6 Units/kg	sc	qd x 14	---	---	---	---
4	10	GBC590B	6.4	iv	D1,2,4,6,8,10,12,14	IFN-α2b	10×10^6 Units/kg	sc	qd x 14
5	10	GBC590B	6.4	iv	D1,2,4,6,8,10,12,14	IFN-α2b	5×10^6 Units/kg	sc	qd x 14
6	10	GBC590B	6.4	iv	D1,2,4,6,8,10,12,14	IFN-α2b	2.5×10^6 Units/kg	sc	qd x 14

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 1: Vehicle (—— mg/kg)



Group 2: [redacted] (6.4 mg/kg) GEM



Group 3: IFN-a2b (10x10e6 U/kg mg/kg)



MAY-26-2000 FRI 10:00 AM SAFESCIENCE INC FAX NO. 6174220675 P. 14

Experiment Number: Pane-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 1: Vehicle (—— mg/kg)



Group 2: GBCS90 (6.4 mg/kg)



Group 3: IFN-a2b (10x10e6 U/kg mg/kg)



MAY-26-2000 FRI 10:00 AM SAFESCIENCE INC FAX NO. 6174220675 P. 14

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 1: Vehicle (—— mg/kg)



Group 2: [redacted] (6.4 mg/kg) GM



Group 3: IFN-α2b (10 x 10e6 U/kg mg/kg)



MAY-22-2000 FRI 10:00 AM SARESCIENCE INC FAX NO. 6174220675

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 1: Vehicle (—— mg/kg)



Group 2: GBCS90 (6.4 mg/kg)



Group 3: IFN-a2b (10x10e6 U/kg mg/kg)



MAY-26-2003 FRI 10:00 AM SAFESCIENCE INC FAX NO. 6174220675 P. 16

MAY-26-2000 FRI 10:01 AM SAFESCIENCE INC FAX NO. 6174220675

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 4: GBCS90 (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg)



Group 5: GBCS90 (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg)



Group 6: GBCS90 (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg)



Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Group 4: [redacted] (6.4 mg/kg) and IFN-a2b (10x10e6 U/kg mg/kg) GM



Group 5: [redacted] (6.4 mg/kg) and IFN-a2b (5x10e6 U/kg mg/kg) GM



Group 6: [redacted] (6.4 mg/kg) and IFN-a2b (2.5x10e6 U/kg mg/kg) GM



APR-20-2000 FRI 10:01 AM SHRESCIENCE INC FAX NO. 6174220675

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Body Weight Change:

Group 1: Vehicle (—— mg/kg)

Date	3/6/00	3/8/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00							
Days	1	4	8	11	15	22	25	29	31	36	39	43	46	50	53	57	60							
Wt 1	24	24.8	23.6	25.8	27.3	26.6	26.9	27.3	27.7	27.7	27.6	Euthanized 4/13/00												
Wt 2	22.1	23.2	22.4	23	23.1	24.4	24.8	Euthanized 3/30/00																
Wt 3	22.4	22.9	23.6	23.9	24.2	23.9	Euthanized 3/27/00																	
Wt 4	23.2	24.4	24.3	24.1	24.6																			
Wt 5	25.3	25.1	26	26	25.9	26.8	27.9	Euthanized 3/30/00																
Wt 6	23.8	24	23.9	24.7	24.5	24.6	25.3	Euthanized 3/30/00																
Wt 7	22	22.3	23	23	23.8	22.9	Euthanized 3/27/00																	
Wt 8	24.8	25.5	24.9	25.1	26.1	25.3	Euthanized 3/27/00																	
Wt 9	24.2	24	24.3	24.4	25.3	24.3	25.1	Euthanized 3/30/00																
Wt 10	23.9	23.5	24.9	18.4	Dead 3/18/00																			
Mean	23.6	24.0	23.9	23.9	25.0	24.9	26.0	27.3	27.7	27.7	27.6													
STDEV	1.1	1.0	1.5	2.1	1.3	1.3	1.3																	

Group 2: GliC590 (6.4 mg/kg)

Date	3/6/00	3/8/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00							
Days	1	4	8	11	15	22	25	29	31	36	39	43	46	50	53	57	60							
Wt 1	24.1	25.6	25.2	25	25.5	25.6	26.1	27.1	28	Euthanized 4/6/00														
Wt 2	24	25	24.8	24.6	25.9	26.1	26	Euthanized 3/16/00																
Wt 3	24.3	25.1	25.9	25.5	26.2	25.7	26	25.8	26.9	Euthanized 4/6/00														
Wt 4	21.4	22.8	22.6	22.2	21.9	22.7	Euthanized 3/27/00																	
Wt 5	21.4	22.7	23.7	23.7	24.1	23.4	Euthanized 3/27/00																	
Wt 6	24.8	25.9	25.9	26.5	27																			
Wt 7	24.3	27.4	28.6	27.8	27.5	27.6	28	27.3	27.4	27.9	27.9	Euthanized 4/13/00												
Wt 8	23.6	23.9	24.6	25.1	25.2																			
Wt 9	23.1	25.4	25.7	26	25.4																			
Wt 10	23	23.4	23.9	23.5	23.1																			
Mean	23.4	24.7	25.1	25.0	25.3	25.2	26.5	26.7	27.4	27.9	27.9													
STDEV	1.2	1.5	1.6	1.6	1.5	1.8	1.0	0.8	0.6															

Group 3: IFN-α2b (10x10e6 U/kg mg/kg)

Date	3/6/00	3/8/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00							
Days	1	4	8	11	15	22	25	29	31	36	39	43	46	50	53	57	60							
Wt 1	20.5	22	22.4	22.5	22.6	21.1	Euthanized 3/23/00																	
Wt 2	20.3	20.9	21.2	21.6	21.2	20.6	20.7	21.7	21.8	21.7	22	Euthanized 4/13/00												
Wt 3	24.1	25.1	25.2	26.5	26.4	25.1	25.7	Euthanized 3/30/00																
Wt 4	23	24.2	24.1	24.7	24.8																			
Wt 5	20.4	21.9	22.1	22.6	22.4	22.6	23.2	Euthanized 3/20/00																
Wt 6	21.8	22.8	22.9	23.7	23.2	23.8	24.3	Euthanized 3/20/00																
Wt 7	28.5	28.3	28.9	29.7	29.9	30.2	29.6	Euthanized 3/20/00																
Wt 8	22.7	23.9	24.1	24.5	25.1																			
Wt 9	25.4	25.5	25.9	26	26.3																			
Wt 10	23.5	24.1	24.4	25.3	25.7																			
Mean	23.0	23.9	24.1	24.7	24.8	23.9	24.7	21.7	21.8	21.7	22.0													
STDEV	2.6	2.1	2.2	2.4	2.5	3.5	3.5																	

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Body Weight Changes

Group 1: Vehicle (—— mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00											
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60										
Wt 1	24	24.8	25.6	25.8	27.1	26.6	26.9	27.3	27.7	27.7	27.6	Euthanized 4/13/00															
Wt 2	22.1	23.2	22.4	23	23.1	24.4	24.8	Euthanized 3/30/00																			
Wt 3	22.4	22.9	23.6	23.9	24.7	23.9	Euthanized 3/27/00																				
Wt 4	23.2	24.4	24.3	24.1	24.6	Euthanized 3/30/00																					
Wt 5	25.1	25.1	26	26	25.9	26.8	27.9	Euthanized 3/30/00																			
Wt 6	23.8	24	23.9	24.7	24.5	24.6	25.3	Euthanized 3/27/00																			
Wt 7	22	22.3	23	23	23.8	22.9	Euthanized 3/27/00																				
Wt 8	24.8	25.5	24.9	25.1	26.1	25.3	Euthanized 3/30/00																				
Wt 9	24.2	24	24.3	24.4	25.3	24.3	25.1	Dead 3/18/00																			
Wt 10	23.9	23.5	20.9	18.8																							
Mean	23.6	24.0	23.9	23.9	25.0	24.9	26.0	27.3	27.7	27.7	27.6																
STDEV	1.1	1.0	1.5	2.1	1.3	1.3	1.3																				

Group 2: [redacted] (6.4 mg/kg) GM

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00											
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60										
Wt 1	24.1	25.6	25.2	25	25.5	25.6	26.1	27.1	28	Euthanized 4/6/00																	
Wt 2	24	25	24.8	24.6	25.9	26.1	26	Euthanized 3/30/00																			
Wt 3	24.3	25.1	25.9	25.5	26.2	25.7	26	25.8	26.9	Euthanized 4/6/00																	
Wt 4	21.4	22.8	22.6	22.2	22.9	22.7	Euthanized 3/27/00																				
Wt 5	21.4	22.7	23.7	23.7	24.1	23.4	Euthanized 3/27/00																				
Wt 6	24.8	25.9	25.9	26.5	27																						
Wt 7	24.3	27.4	28.6	27.8	27.5	27.6	28	27.3	27.4	27.9	27.9	Euthanized 4/13/00															
Wt 8	23.6	23.9	24.6	25.1	25.2																						
Wt 9	23.1	25.4	25.7	26	25.4																						
Wt 10	23	23.4	25.9	23.5	23.1																						
Mean	23.4	24.7	25.1	25.0	25.3	25.2	26.5	26.7	27.4	27.9	27.9																
STDEV	1.2	1.5	1.6	1.6	1.5	1.8	1.0	0.8	0.6																		

Group 3: IFN-a2b (10x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00											
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60										
Wt 1	20.5	22	22.4	22.5	22.6	21.1	Euthanized 3/27/00																				
Wt 2	20.3	20.9	21.2	21.6	21.2	20.6	20.7	21.7	21.8	21.7	22	Euthanized 4/13/00															
Wt 3	24.1	25.1	25.2	26.5	26.4	25.1	25.7	Euthanized 3/30/00																			
Wt 4	23	24.2	24.1	24.7	24.8	Euthanized 3/20/00																					
Wt 5	20.4	21.9	22.1	22.6	22.4	22.6	23.2	Euthanized 3/20/00																			
Wt 6	21.8	22.8	22.9	23.7	23.2	23.8	24.3	Euthanized 3/20/00																			
Wt 7	28.5	28.3	25.9	29.7	29.9	30.2	29.6	Euthanized 3/20/00																			
Wt 8	22.7	23.9	24.1	24.5	25.1																						
Wt 9	25.4	25.5	25.9	26	26.3																						
Wt 10	23.5	24.1	24.4	25.3	25.7																						
Mean	23.0	23.9	24.1	24.7	24.8	23.9	24.7	21.7	21.8	21.7	22.0																
STDEV	2.6	2.1	2.2	2.4	2.5	3.5	3.5																				

FAX NO. 6174220675

Experiment Number: Panc-e10; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Body Weight Changes

Group 4: GBCS90 (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/5/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/8/00							
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60							
Wt 1	24.3	24.8	24.5	24.6	24.7	24.8	26.4	27.4	27.8	27.7	Euthanized 4/10/00													
Wt 2	23.1	24.5	24.1	24.2	24.1	24.7	Euthanized 3/27/00																	
Wt 3	22.2	23.6	23.1	23.1	23.1	23.1	24.2	Euthanized 3/30/00																
Wt 4	23.6	24	22.5	21.9	21.5	23.1	24.3	23.5	22.8	22.3	22	23.6	23.4	23.1	27.6	23.9	23.4							
Wt 5	23	23.9	22.6	24	24																			
Wt 6	23.2	27.6	23.3	23.8	23.6	23.7	Euthanized 3/27/00																	
Wt 7	23.8	24.8	24.5	25.4	25.6	25	Euthanized 3/30/00																	
Wt 8	26.6	36.6	26.9	26.6	25.9																			
Wt 9	24.6	24.9	24.9	24.4	24																			
Wt 10	21.5	22.5	23	23.1	23.2	24.5	Euthanized 3/27/00																	
Mean	23.6	24.3	24.0	24.1	24.0	24.1	25.0	25.5	25.3	25.0	22.0	23.6	23.4	23.1	23.6	23.9	23.4							
STDEV	1.4	4.3	1.3	1.3	1.3	0.8	1.1	1.9	3.5	3.8														

Group 5: GBCS90 (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/5/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/8/00							
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60							
Wt 1	24.7	25.6	26.1	25.9	26.8	26.5	Euthanized 3/27/00																	
Wt 2	24.8	25.7	25.9	25.8	25.5	25.7	26.8	27.2	26	26.2	27.7	28.1	28.9	27.9	27.6	28.6	29.9							
Wt 3	24	24.8	24.9	24.5	23.9																			
Wt 4	23.2	24	23.7	23.8	24.1	23.1	23.4	23.6	24.2	24.4	24.9	24.7	24.6	24.8	25.2	25.4	25.7							
Wt 5	28.2	29.1	29.3	29.7	29.5	30.1	30.7	Euthanized 3/30/00																
Wt 6	25.1	25.6	25.3	25.4	26.1	25	Euthanized 3/27/00																	
Wt 7	23.6	24.9	24.8	25.1	26.9	26.2	26.4	Euthanized 3/30/00																
Wt 8	22.2	23.1	23.6	23.5	23.4																			
Wt 9	26.3	27.4	28.5	27.6	27.6																			
Wt 10	23.4	23	22.6	22	22.5	23.1	22.8	Euthanized 3/30/00																
Mean	24.6	25.3	25.5	25.3	25.6	25.4	26.0	25.4	25.1	25.3	26.3	26.4	26.8	26.4	26.4	27.0	27.8							
STDEV	1.7	1.9	2.1	2.2	2.2	2.9	3.2	2.5	1.3	1.3	2.0	2.4	3.0	2.2	1.7	2.3	3.0							

Group 6: GBCS90 (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/5/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/8/00							
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60							
Wt 1	22.9	23	23.9	23.7	24	23.9	25	25.3	Euthanized 4/5/00															
Wt 2	24.1	26.3	24.8	25.4	25.9	24.9	25.2	25.4	25.6	Euthanized 4/5/00														
Wt 3	26.5	26.6	26.6	28.4	29.2	28.9	28.5	28.1	28.4	28	29.7	28.9	29.2	29.4	29.5	29.4	29.8							
Wt 4	23.7	24.4	24.4	23.6	25	24.9	25	24.9	25.1	24.9	25.6	25.6	25.7	26.4	27.4	26.6	26.3							
Wt 5	22	23	22.8	22.2	22	23	Euthanized 3/27/00																	
Wt 6	24.6	25.3	25	24.3	25.6																			
Wt 7	24.7	24.9	25.3	26.8	27.2																			
Wt 8	23.9	26.1	25.3	25.5	26.3																			
Wt 9	24.3	26	25.8	26	26.4																			
Wt 10	23.1	23.9	23.2	21.9	22.3																			
Mean	24.8	25.0	24.7	24.8	25.4	25.1	25.9	25.9	26.4	26.5	27.7	27.3	27.5	27.9	28.5	28.0	28.1							
STDEV	1.2	1.3	1.2	2.0	2.2	2.3	1.7	1.5	1.8	2.2	2.9	2.3	2.5	2.1	1.5	2.0	2.5							

MAY-26-2000 FRI 10:01 AM SAREGLENCE INC FAX NO. 6174220675 P. 19

Experiment Number: Panc-e20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Body Weight Changes

Group 4: [redacted] (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg) GM

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	24.1	24.8	24.5	24.6	24.7	24.8	26.4	27.4	27.8	27.7	Euthanized 4/10/00						
Wt 2	23.1	24.5	24.1	24.2	24.1	24.7	Euthanized 3/27/00										
Wt 3	22.2	23.6	23.8	23.1	23.1	23.1	24.2	Euthanized 3/30/00									
Wt 4	23.6	24	22.5	21.9	21.5	23.1	24.3	23.5	22.8	22.3	22	23.6	23.4	23.1	23.6	23.9	23.4
Wt 5	23	23.9	23.6	24	24												
Wt 6	23.2	23.6	23.3	23.8	23.6	23.7	Euthanized 3/27/00										
Wt 7	23.8	24.8	24.5	25.4	25.6	25	Euthanized 3/27/00										
Wt 8	26.6	26.6	26.9	26.6	25.9												
Wt 9	24.6	24.9	24.8	24.4	24												
Wt 10	21.5	22.5	23	23.1	23.2	24.5	Euthanized 3/27/00										
Mean	23.6	24.3	24.0	24.1	24.0	24.1	25.0	25.5	25.3	25.0	22.0	23.6	23.4	23.1	23.6	23.9	23.4
STDEV	1.4	1.1	1.3	1.3	1.3	0.8	1.2	2.8	3.5	3.8							

Group 5: [redacted] (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg) GM

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	24.7	25.6	26.1	25.9	26.8	26.5	Euthanized 3/27/00										
Wt 2	24.8	25.7	25.9	25.8	25.5	25.7	26.8	27.2	26	26.2	27.7	28.1	28.9	27.9	27.6	28.6	29.9
Wt 3	24	24.8	24.9	24.5	23.9												
Wt 4	23.2	24	23.7	23.8	24.1	23.1	23.4	23.6	24.2	24.4	24.9	24.7	24.6	24.8	25.2	25.6	25.7
Wt 5	28.2	29.1	29.3	29.7	29.5	30.1	30.7	Euthanized 3/30/00									
Wt 6	25.1	25.6	25.3	25.4	26.1	25	Euthanized 3/27/00										
Wt 7	23.6	24.9	24.8	25.1	26.9	26.2	26.4	Euthanized 3/30/00									
Wt 8	22.2	23.1	23.8	23.5	23.4												
Wt 9	26.3	27.4	28.5	27.6	27.6												
Wt 10	23.4	23	22.6	22	22.5	21.1	22.8	Euthanized 3/30/00									
Mean	24.6	25.3	25.5	25.3	25.6	25.4	26.8	25.4	25.1	25.3	26.3	26.4	26.8	26.4	26.4	27.0	27.8
STDEV	1.7	1.9	2.1	2.2	2.2	2.8	3.2	2.5	1.3	1.3	2.8	2.4	3.0	2.2	1.7	2.3	3.0

Group 6: [redacted] (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg) GM

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	22.9	23	23.9	23.7	24	23.9	25	25.1	Euthanized 4/3/00								
Wt 2	24.1	26.3	24.8	25.4	25.9	24.9	25.2	25.4	25.6	Euthanized 4/6/00							
Wt 3	26.5	26.6	26.6	28.4	29.2	28.9	28.5	28.1	28.4	28	29.7	28.9	29.2	29.4	29.5	29.4	29.8
Wt 4	23.7	24.4	24.4	23.6	25	24.9	25	24.9	25.1	24.9	25.6	25.6	25.7	26.4	27.4	26.6	26.3
Wt 5	22	23	22.8	22.2	22	23	Euthanized 3/27/00										
Wt 6	24.6	25.3	25	24.3	25.6												
Wt 7	24.7	24.9	25.3	26.8	27.2												
Wt 8	23.9	26.1	25.3	25.5	26.3												
Wt 9	24.3	26	25.8	26	26.4												
Wt 10	23.1	23.9	23.2	21.9	22.3												
Mean	24.0	25.0	24.7	24.8	25.4	25.1	25.9	25.9	26.4	26.5	27.7	27.3	27.5	27.9	28.5	28.0	28.1
STDEV	1.2	1.3	1.2	2.0	2.2	2.3	1.7	1.5	1.8	2.2	2.9	2.3	2.5	2.1	1.5	2.0	2.5

FAX NO. 6174220675 P. 19

Experiment Number: Panc-e20; Technician(s): R. Bult; The Experiment Started on: 3/6/2000

Body Weight Changes

Group 4: GBC590 (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	24.3	24.8	24.5	24.6	24.7	24.8	26.4	27.4	27.8	27.7	Euthanized 4/10/00						
Wt 2	23.1	24.5	24.1	24.2	24.1	24.7	Euthanized 3/27/00										
Wt 3	22.2	23.6	23.8	23.1	23.1	23.1	24.2	Euthanized 3/30/00									
Wt 4	23.6	24	22.5	21.9	21.5	23.1	24.3	23.5	22.8	22.3	22	23.6	23.4	23.1	23.6	23.9	23.4
Wt 5	23	23.9	23.6	24	24												
Wt 6	23.2	23.6	23.3	23.8	23.6	23.7	Euthanized 3/27/00										
Wt 7	23.8	24.5	24.5	25.4	25.6	25	Euthanized 3/27/00										
Wt 8	26.6	26.6	26.9	26.6	25.9												
Wt 9	24.6	24.9	24.8	24.4	24												
Wt 10	21.5	22.5	23	23.1	23.2	24.5	Euthanized 3/27/00										
Mean	23.6	24.3	24.0	24.1	24.0	24.1	25.0	25.5	25.3	25.0	22.0	23.6	23.4	23.1	23.6	23.9	23.4
STDEV	1.4	1.3	1.3	1.3	1.3	0.8	1.2	2.9	3.5	3.8							

Group 5: GBC590 (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	24.7	25.6	26.1	25.9	26.8	26.5	Euthanized 3/27/00										
Wt 2	24.8	25.7	25.9	25.8	25.5	25.7	26.8	27.2	26	26.2	27.7	28.1	28.9	27.9	27.6	28.6	29.9
Wt 3	24	24.8	24.9	24.5	23.9												
Wt 4	23.2	24	23.7	23.8	24.1	23.1	23.4	23.6	24.2	24.4	24.9	24.7	24.6	24.8	25.2	25.4	25.7
Wt 5	28.2	29.1	29.3	29.7	29.5	30.1	30.7	Euthanized 3/30/00									
Wt 6	25.1	25.6	25.3	25.4	26.1	25	Euthanized 3/27/00										
Wt 7	23.6	24.9	24.8	25.1	26.9	26.2	26.4	Euthanized 3/30/00									
Wt 8	22.2	23.1	23.8	23.5	23.4												
Wt 9	26.3	27.4	28.5	27.6	27.6												
Wt 10	23.4	23	22.6	22	22.5	23.1	22.8	Euthanized 3/30/00									
Mean	24.6	25.3	25.5	25.3	25.6	25.4	26.0	25.4	25.4	25.3	26.3	26.4	26.8	26.4	26.4	27.0	27.8
STDEV	1.7	1.9	2.1	2.2	2.2	2.8	3.2	2.5	1.3	1.3	2.8	2.4	3.0	2.2	1.7	2.3	3.0

Group 6: GBC590 (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg)

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Wt 1	23.9	23	23.9	23.7	24	23.9	25	25.1	Euthanized 4/3/00								
Wt 2	24.1	24.3	24.8	25.4	25.9	24.9	25.2	25.4	25.6	Euthanized 4/6/00							
Wt 3	26.5	26.6	26.6	28.4	29.2	28.9	28.5	28.1	28.4	28	29.7	28.9	29.2	29.4	29.5	29.4	29.8
Wt 4	23.7	24.4	24.4	23.6	25	24.9	25	24.9	25.1	24.9	25.6	25.6	25.7	26.4	27.4	26.6	26.3
Wt 5	22	23	22.8	22.2	22	23	Euthanized 3/27/00										
Wt 6	24.6	25.3	25	24.3	25.6												
Wt 7	24.7	24.9	25.3	26.8	27.2												
Wt 8	23.9	26.1	25.3	25.5	26.3												
Wt 9	24.3	26	25.8	26	26.4												
Wt 10	23.1	23.9	23.2	23.9	22.3												
Mean	24.0	25.0	24.7	24.8	25.4	25.1	25.9	25.9	26.4	26.5	27.7	27.3	27.5	27.9	28.5	28.0	28.1
STDEV	1.2	1.3	1.2	2.0	2.2	2.3	1.7	1.5	1.8	2.2	2.9	2.3	1.5	2.1	1.5	2.0	2.5

MAY-26-2000 FRI 10:01 AM SARKISIANE INC FAX NO. 6174220675

Experiment Number: Panc-c20; Technician(s): R. Ball; The Experiment Started on: 3/6/2000

Body Weight Changes

Mean Body Weight of Mice in Different Study Group

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Gp 1	23.6	24.0	23.9	23.9	25	24.9	26	27.3	27.7	27.7	27.6						
Gp 2	23.4	24.7	25.1	23	25.3	25.2	26.5	26.7	27.4	27.9	27.9						
Gp 3	23	23.9	24.1	24.7	24.8	23.9	24.7	21.7	21.8	21.7	22						
Gp 4	23.6	24.3	24	24.1	24	24.1	25	25.5	25.3	25	22	23.6	23.4	23.1	23.6	23.9	23.6
Gp 5	24.6	25.3	25.5	25.3	25.6	25.4	26	25.4	25.1	25.3	26.3	26.4	26.8	26.4	26.4	27	27.8
Gp 6	24	25	24.7	24.8	25.4	25.1	25.9	25.9	26.4	26.5	27.7	27.3	27.5	27.9	28.5	28	28.1

Percent Mean Body Weight Change

Date	3/6/00	3/9/00	3/13/00	3/16/00	3/20/00	3/27/00	3/30/00	4/3/00	4/6/00	4/10/00	4/13/00	4/17/00	4/20/00	4/24/00	4/27/00	5/1/00	5/4/00
Days	1	4	8	11	15	22	25	29	32	36	39	43	46	50	53	57	60
Gp 1	0.0%	1.7%	1.3%	1.3%	5.9%	5.5%	10.2%	15.7%	17.4%	17.4%	16.9%						
Gp 2	0.0%	5.6%	7.3%	6.8%	8.1%	7.7%	13.2%	14.1%	17.1%	19.2%	19.2%						
Gp 3	0.0%	3.9%	4.8%	7.4%	7.8%	3.9%	7.4%	-5.7%	-5.2%	-5.7%	-4.3%						
Gp 4	0.0%	3.0%	1.7%	2.1%	1.7%	2.1%	5.9%	8.1%	7.2%	5.9%	-6.8%	0.0%	-0.8%	-2.1%	0.0%	1.3%	-0.8%
Gp 5	0.0%	2.8%	3.7%	2.8%	4.1%	3.3%	5.7%	3.3%	2.0%	2.8%	6.9%	7.3%	8.9%	7.3%	7.3%	9.8%	13.0%
Gp 6	0.0%	4.2%	2.9%	3.3%	5.8%	4.6%	7.9%	7.9%	10.0%	10.4%	15.4%	13.8%	14.6%	16.3%	18.8%	16.7%	17.1%

FDA NO. 81/422b/5

P. 20

Experiment Number: Panc-e20; Technician(s): R. Ball; Calculation of Time For Tumor To Grow To 1.2 Gram

Group 1: Vehicle (—— mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/16/09	17	s	14	1183	4/28/09	19	s	15	1476	33	36.2
2	3/27/09	12	n	13	938	3/29/09	14	s	14	1073	15	33.9
3	3/27/09	12	s	14	1187	3/29/09	13	s	15	1367.5	22	36.8
4	3/27/09	12	s	13	956	3/29/09	12	s	15	1367.5	18	17.4
5	3/27/09	12	s	14	1085	3/29/09	14	s	15	1430	21	22.2
6	3/27/09	12	s	14	1206	3/29/09	14	s	15	1430	21	37.2
7	3/27/09	12	s	14	1093	3/29/09	12	s	16	1080	22	36.1
8	3/27/09	12	s	13	1090.5	3/29/09	14	s	14	1305	22	36.8
9	3/27/09	14	s	14	821	3/29/09	13	s	15	1367.5	21	34.3
10	3/27/09		s		dead-1			s				

Mean Day of Tumor Reach 1.2 g	1424.5	24.8	27.6
SEM	204	1.9	1.9
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 2: GBCS98 (6.4 mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/3/09	12	s	14	1009	4/16/09	13	s	15	1481.5	22	29.9
2	3/27/09	12	s	14	1095	3/29/09	13	s	15	1367.5	26	24.7
3	4/7/09	13	s	14	1045	4/9/09	13	s	15	1367.5	32	31.3
4	3/27/09	12	s	13	794.5	3/27/09	13	s	15	1367.5	20	29.1
5	3/27/09	12	s	14	1321	3/27/09	15	s	16	1393	23	29.2
6	3/29/09	12	s	14	1064	3/29/09	13	s	15	1367.5	30	17.2
7	4/9/09	12	s	15	1009	4/9/09	13	s	15	1367.5	29	27.5
8	3/28/09	11	s	13	923.5	3/29/09	15	s	15	1352	18	17.9
9	3/25/09	12	s	14	1158	3/25/09	14	s	15	1066	15	15.3
10	3/29/09	12	s	14	1193	3/29/09	13	s	16	1393	13	15.3

Mean Day of Tumor Reach 1.2 g	1334.5	24.4	23.8
SEM	91.8	2.4	2.4
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			0

Group 3: IFN-α2b (10x10e6 U/kg = mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	3/23/09	11	s	13	961.5	3/27/09	14	s	15	1430	22	25.4
2	4/16/09	13	s	14	1063	4/28/09	14	s	14	1092	30	36.3
3	3/27/09	13	s	14	1020	3/29/09	13	s	15	1367.5	25	24.1
4	3/26/09	13	s	13	984.5	3/29/09	13	s	15	1367.5	18	17.4
5	3/27/09	13	s	14	1249	3/29/09	13	s	15	1435.5	25	23.9
6	3/27/09	12	s	14	1008	3/29/09	13	s	16	1352	29	23.7
7	3/27/09	12	s	14	1063	3/29/09	14	s	15	1430	22	23.1
8	3/27/09	13	s	14	1020	3/29/09	13	s	15	1367.5	22	37.2
9	3/26/09	13	s	13	938	3/29/09	13	s	13	1367.5	23	37.4
10	3/26/09	13	s	14	1020	3/29/09	13	s	16	1393	24	23.7

Mean Day of Tumor Reach 1.2 g	1493.5	23.2	23.9
SEM	25.1	2.6	1.4
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			0

Group 4: GBCS98 (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/6/09	13	s	14	1083	4/16/09	15	s	16	1506	36	33.1
2	3/23/09	12	s	13	956	3/27/09	13	s	15	1367.5	21	31.3
3	3/27/09	12	s	14	1008	3/29/09	14	s	15	1430	21	27.5
4			s					s				
5	3/29/09	11	s	13	1004.5	4/2/09	13	s	15	1367.5	48	37.6
6	3/23/09	12	s	14	1095	3/29/09	13	s	15	1367.5	22	31.8
7	3/27/09	12	s	13	971.5	3/27/09	13	s	16	1352	22	36.5
8	3/29/09	12	s	14	1205	4/2/09	13	s	16	1352	24	14.9
9	3/23/09	11	s	14	940	3/27/09	13	s	15	1367.5	24	17.9
10	3/27/09	12	s	14	1109	3/27/09	14	s	15	1080	22	36.1

Mean Day of Tumor Reach 1.2 g	1427.5	23.6	29.9
SEM	77.9	1.9	3.6
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 5: GBCS98 (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	3/27/09	12	s	14	1008	3/27/09	13	s	16	1506	22	30.4
2			s		—			s				
3	3/25/09	12	s	13	794.5	3/29/09	13	s	15	1367.5	14	17.6
4			s					s				
5	3/27/09	12	s	14	1021	3/27/09	13	s	16	1506	22	22.1
6	3/27/09	12	s	14	1008	3/27/09	13	s	15	1367.5	22	31.9
7	3/27/09	12	s	13	1008.5	3/30/09	16	s	15	1602.5	25	32.3
8	3/29/09	11	s	14	1007	3/29/09	15	s	16	1352	20	17.6
9	3/29/09	12	s	14	1007	3/29/09	13	s	15	1367.5	20	37.9
10	3/27/09	12	s	14	1006	3/27/09	13	s	15	1367.5	25	34.2

Mean Day of Tumor Reach 1.2 g	1454.5	23.4	30.5
SEM	17.2	1.1	1.9
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 6: GBCS98 (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg)

Mouse	Below 1.2 g, or Dead: Date	w	c	t	Wt (mg)	Greater than 1.2 g: Date	w	c	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	3/30/09	11	s	14	987	4/7/09	13	s	15	1367.5	29	35.5
2	4/9/09	12	s	13	1008	4/16/09	14	s	16	1506	32	29.7
3			s					s				
4			s					s				
5	3/23/09	12	s	14	1095	3/27/09	13	s	16	1506.5	22	22.9
6	3/29/09	11	s	14	967	3/29/09	13	s	15	1367.5	20	37.5
7	3/23/09	12	s	15	986	3/29/09	13	s	15	1367.5	18	17.4
8	3/29/09	13	s	13	967	3/29/09	13	s	13	1367.5	25	17.3
9	3/29/09	13	s	14	1007	3/29/09	14	s	13	1066	13	13.1
10	3/26/09	12	s	14	1006	3/23/09	14	s	15	1066	28	13.9

Mean Day of Tumor Reach 1.2 g	1494.5	21.4	20.7
SEM	93.5	2.9	2.9
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Experiment Number: Panc-e20; Technician(s): R. Ball; Calculation of Time For Tumor To Grow To 1.2 Gram

Group 1: Vehicle (—— mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/14/00	17	s	34	1187	4/13/00	16	s	35	1436	33	30.1
2	3/27/00	13	s	33	936	3/30/00	14	s	34	1317	35	27.8
3	3/23/00	12	s	34	1181	3/23/00	13	s	33	1367.5	32	36.9
4	3/20/00	11	s	33	936	3/23/00	13	s	33	1367.5	39	37.4
5	3/27/00	13	s	34	1183	3/30/00	14	s	35	1436	35	27.1
6	3/27/00	13	s	34	1366	3/30/00	14	s	35	1436	35	27.1
7	3/23/00	13	s	34	1181	3/23/00	13	s	33	1367.5	32	36.9
8	3/23/00	12	s	33	1366	3/30/00	14	s	35	1436	37	27.1
9	3/16/00	11	s	32	1187	3/23/00	13	s	33	1367.5	37	36.9
10	3/20/00	11	s	32	1187	died-1		s				

Mean Day of Tumor Reach 1.2 g	34.3	34.4	33.6
SEM	1.9	1.9	1.9
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 2: GBCS90 (6.4 mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/7/00	12	s	34	1004	4/6/00	13	s	35	1481.5	32	30.8
2	3/27/00	12	s	34	1098	3/30/00	13	s	35	1367.5	35	34.7
3	4/3/00	12	s	34	1066	4/6/00	13	s	33	1367.5	32	31.3
4	3/23/00	10	s	33	916.3	3/27/00	12	s	35	1367.5	32	29.1
5	3/23/00	12	s	34	1301	3/27/00	13	s	35	1367.5	32	29.7
6	3/20/00	12	s	34	1066	3/23/00	13	s	35	1367.5	34	33.2
7	4/10/00	12	s	35	1066	4/13/00	13	s	33	1293.5	39	37.9
8	3/30/00	11	s	33	937.5	3/23/00	13	s	35	1792	38	37.9
9	3/27/00	12	s	34	1131	3/23/00	14	s	33	1066	35	33.7
10	3/20/00	11	s	34	1193	3/27/00	13	s	35	1351	38	35.3

Mean Day of Tumor Reach 1.2 g	33.4	34.4	33.8
SEM	0.8	2.4	2.4
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			0

Group 3: IFN-α2b (10x10e6 U/kg mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	3/23/00	11	s	33	783.3	3/27/00	12	s	35	1098	37	26.4
2	4/10/00	13	s	34	1193	4/13/00	12	s	34	1193	39	36.9
3	3/23/00	11	s	34	1098	3/30/00	13	s	35	1367.5	35	34.1
4	3/16/00	11	s	33	786.3	3/23/00	13	s	35	1367.5	34	37.6
5	3/23/00	12	s	35	1066	3/30/00	13	s	33	1435.5	35	33.9
6	3/27/00	12	s	34	1066	3/30/00	13	s	34	1193	35	33.3
7	3/27/00	13	s	34	1183	3/30/00	14	s	35	1436	35	33.1
8	3/23/00	11	s	34	1098	3/30/00	13	s	35	1367.5	38	37.1
9	3/16/00	11	s	33	936	3/23/00	13	s	33	1367.5	35	37.4
10	3/20/00	11	s	33	1098	3/23/00	13	s	33	1367.5	34	35.7

Mean Day of Tumor Reach 1.2 g	35.3	35.9	34.9
SEM	1.3	1.5	1.5
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			0

Group 4: GBCS90 (6.4 mg/kg) and IFN-α2b (10x10e6 U/kg mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	4/3/00	13	s	34	1183	4/13/00	15	s	36	1898	36	33.1
2	3/23/00	12	s	33	936	3/27/00	13	s	33	1367.5	32	31.1
3	3/27/00	13	s	34	1908	3/30/00	14	s	35	1436	35	33.1
4			s					s				
5	3/27/00	11	s	33	1066.5	3/27/00	13	s	33	1293.5	38	37.6
6	3/23/00	12	s	34	1066	3/27/00	13	s	33	1367.5	32	31.0
7	3/23/00	11	s	33	933.5	3/23/00	13	s	36	1352	31	30.6
8	3/23/00	12	s	34	1066	3/27/00	13	s	34	1352	35	35.7
9	3/20/00	11	s	34	843	3/23/00	13	s	33	1293.5	38	37.5
10	3/27/00	13	s	34	1187	3/27/00	13	s	33	1293	35	36.1

Mean Day of Tumor Reach 1.2 g	34.7	35.6	34.9
SEM	0.9	1.9	1.6
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 5: GBCS90 (6.4 mg/kg) and IFN-α2b (5x10e6 U/kg mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
2	3/27/00	12	s	34	1098	3/27/00	13	s	34	1366	32	29.4
3			s		—			s				
3	3/20/00	11	s	33	766.3	3/23/00	13	s	33	1367.5	38	37.6
4			s					s				
5	3/27/00	13	s	34	1301	3/23/00	13	s	34	1367.5	35	33.1
6	3/27/00	12	s	34	1098	3/27/00	13	s	33	1367.5	32	31.0
7	3/27/00	13	s	33	1098.5	3/30/00	13	s	33	1367.5	35	33.3
8	3/20/00	11	s	33	909.5	3/23/00	13	s	36	1352	38	33.0
9	3/20/00	12	s	34	1066	3/23/00	13	s	35	1367.5	38	33.2
10	3/27/00	12	s	34	1066	3/23/00	13	s	35	1293.5	35	34.2

Mean Day of Tumor Reach 1.2 g	34.5	35.0	34.0
SEM	1.2	1.1	1.0
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Group 6: GBCS90 (6.4 mg/kg) and IFN-α2b (2.5x10e6 U/kg mg/kg)

Mo	Below 1.2 g or Dead: Date	w	s	t	Wt (mg)	Greater than 1.2 g: Date	w	s	t	Wt (mg)	Days to 1.2 g: Obs.	Calc.
1	3/30/00	11	s	34	847	4/3/00	13	s	35	1367.5	39	35.6
2	4/3/00	13	s	35	1080	4/6/00	14	s	36	1568	32	39.7
3			s					s				
4			s					s				
5	3/23/00	12	s	34	1098	3/23/00	13	s	33	1367.5	37	33.0
6	3/20/00	11	s	34	847	3/23/00	13	s	35	1367.5	36	37.5
7	3/23/00	12	s	35	936	3/23/00	13	s	35	1293.5	38	37.4
8	3/20/00	11	s	33	843	3/23/00	13	s	33	1367.5	38	37.9
9	3/20/00	13	s	34	1193	3/23/00	14	s	33	1066	33	33.1
10	3/20/00	12	s	34	1098	3/23/00	14	s	33	1066	34	33.9

Mean Day of Tumor Reach 1.2 g	34.3	35.6	34.9
SEM	1.1	2.9	2.9
# Toxic Death			0
No. of Mice Whose Tumors Have Not Reached 1.2 g			1

Fleishman Research Center

FAX NO. 6174220675